Concord Drugs Share Price
Start SIP in Concord Drugs
Start SIPConcord Drugs Performance
Day Range
- Low 0
- High 0
52 Week Range
- Low 0
- High 0
- Open Price0
- Previous Close0
- Volume
Concord Drugs Investment Rating
-
Master Rating:
-
Concord Biotech Ltd has an operating revenue of Rs. 1,037.91 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 40% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 9% and 25% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 6% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 74 which is a FAIR score but needs to improve its earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 107 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 6 | 14 | 13 | 7 | 9 | 12 |
| Operating Expenses Qtr Cr | 6 | 14 | 12 | 6 | 7 | 11 |
| Operating Profit Qtr Cr | 1 | 0 | 1 | 2 | 1 | 1 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit Qtr Cr | 0 | 0 | 0 | 1 | 0 | 0 |
Concord Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹37.06
- 50 Day
- ₹37.10
- 100 Day
- ₹37.46
- 200 Day
- ₹37.44
- 20 Day
- ₹37.27
- 50 Day
- ₹36.71
- 100 Day
- ₹37.72
- 200 Day
- ₹39.44
Concord Drugs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 37.83 |
| Second Resistance | 38.73 |
| Third Resistance | 39.51 |
| RSI | 49.13 |
| MFI | 33.35 |
| MACD Single Line | 0.10 |
| MACD | 0.08 |
| Support | |
|---|---|
| First Support | 36.15 |
| Second Support | 35.37 |
| Third Supoort | 34.47 |
Concord Drugs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 8,737 | 763,963 | 87.44 |
| Week | 10,483 | 873,612 | 83.34 |
| 1 Month | 10,600 | 859,660 | 81.1 |
| 6 Month | 15,780 | 1,032,621 | 65.44 |
Concord Drugs Result Highlights
Concord Drugs Synopsis
NSE-Medical-Biomed/Biotech
Concord Biotech Ltd. is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1016.94 Cr. and Equity Capital is Rs. 10.46 Cr. for the Year ended 31/03/2024. Concord Biotech Ltd. is a Public Limited Listed company incorporated on 23/11/1984 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is U24230GJ1984PLC007440 and registration number is 007440.| Market Cap | 20,124 |
| Sales | 1,038 |
| Shares in Float | 5.86 |
| No of funds | 99 |
| Yield | 0.45 |
| Book Value | 13.19 |
| U/D Vol ratio | 2.9 |
| LTDebt / Equity | |
| Alpha | 0.2 |
| Beta | 0.61 |
Concord Drugs Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 | Sep-23 |
|---|---|---|---|---|
| Promoters | 44.08% | 44.08% | 44.08% | 44.08% |
| Mutual Funds | 5.26% | 5.15% | 5.65% | 5.58% |
| Insurance Companies | 4.53% | 2.88% | 2.47% | 2.26% |
| Foreign Portfolio Investors | 7.11% | 6.49% | 7% | 7.3% |
| Individual Investors | 7.65% | 7.08% | 6.76% | 6.78% |
| Others | 31.37% | 34.32% | 34.04% | 34% |
Concord Drugs Management
| Name | Designation |
|---|---|
| Mr. Sudhir Vaid | Chairman & Managing Director |
| Mr. Ankur Vaid | Joint Managing Director & CEO |
| Mr. Ravi Kapoor | Non Executive Director |
| Mr. Rajiv Ambrish Agarwal | Non Executive Director |
| Mrs. Bharti Khanna | Independent Director |
| Mr. Amitabh Thakore | Independent Director |
| Mr. Arvind Agarwal | Independent Director |
| Mr. Jayaram Easwaran | Independent Director |
| Dr. Mandayam Chakravarthy Sriraman | Independent Director |
Concord Drugs Forecast
Price Estimates
Concord Drugs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-09 | Quarterly Results | |
| 2024-05-30 | Audited Results | (Revised) |
| 2024-02-13 | Quarterly Results | |
| 2023-11-14 | Quarterly Results | |
| 2023-08-14 | Quarterly Results |
Concord Drugs FAQs
What is Share Price of Concord Drugs ?
Concord Drugs share price is ₹37 As on 05 October, 2024 | 04:34
What is the Market Cap of Concord Drugs ?
The Market Cap of Concord Drugs is ₹37.6 Cr As on 05 October, 2024 | 04:34
What is the P/E ratio of Concord Drugs ?
The P/E ratio of Concord Drugs is 4122.8 As on 05 October, 2024 | 04:34
What is the PB ratio of Concord Drugs ?
The PB ratio of Concord Drugs is 1.1 As on 05 October, 2024 | 04:34